

Neuralstem, Inc.  
Form 8-K  
June 18, 2014

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 18, 2014**

**Neuralstem, Inc.**

**(Exact name of registrant as specified in Charter)**

<b>Delaware</b>	<b>000-1357459</b>	<b>52-2007292</b>
<b>(State or other jurisdiction of incorporation or organization)</b>	<b>(Commission File No.)</b>	<b>(IRS Employee Identification No.)</b>

**9700 Great Seneca Highway,**

**Rockville, Maryland 20850**

**(Address of Principal Executive Offices)**

**(301) 366-4841**

**(Issuer Telephone number)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On June 18, 2014, Neuralstem, Inc. announced that final data from its NSI-189 Phase Ib study in major depressive disorder was presented yesterday at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida. The abstract of the information presented can be found on page 73 of the abstract book <http://ascpmeeting.org/wp-content/uploads/2014/05/ASCP-Oral-Abstract-Book-Online.pdf>. A copy of the press release is attached to this report as Exhibit 99.01.

**Item 9.01 Financial Statement and Exhibits.**

**Exhibit  
Number Description**

99.01 Press Release Dated June 18, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By: /s/ I. Richard Garr  
I. Richard Garr  
Chief Executive Officer

Dated: June 18, 2014



**INDEX OF EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.01	Press Release Dated June 18, 2014